T-cell immunotherapy: looking forward.
Jacqueline Corrigan-Curay,Hans-Peter Kiem,David Baltimore,Marina O'Reilly,Renier J. Brentjens,Laurence J.N. Cooper,Stephen J. Forman,Stephen Gottschalk,Philip D. Greenberg,Richard P. Junghans,Helen E. Heslop,Michael C. Jensen,Crystal L. Mackall,Carl H. June,Oliver W. Press,Daniel J. Powell,Antoni Ribas,Steven A. Rosenberg,Michel Sadelain,Brian G. Till,Amy P. Patterson,Robert Jambou,Eugene Rosenthal,Linda Gargiulo,Maureen Montgomery,Donald B. Kohn +25 more
Reads0
Chats0
TLDR
The T Cell Immunotherapy: Optimizing T-cell trial design workshop as discussed by the authors was a workshop sponsored by the National Institutes of Health's Office of Biotechnology Activities (OBA), which brought together researchers to discuss the scientific advances and share new data on key trial design issues.About:
This article is published in Molecular Therapy.The article was published on 2014-09-01 and is currently open access. It has received 58 citations till now. The article focuses on the topics: Population.read more
Citations
More filters
Journal ArticleDOI
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport,Edward A. Stadtmauer,Gwendolyn Binder-Scholl,Olga Goloubeva,Dan T. Vogl,Simon F. Lacey,Ashraf Badros,Alfred L. Garfall,Brendan M. Weiss,Jeffrey Finklestein,Irina Kulikovskaya,Sanjoy K. Sinha,Shari Kronsberg,Minnal Gupta,Sarah Bond,Luca Melchiori,Joanna E. Brewer,Alan D. Bennett,Andrew B. Gerry,Nicholas J. Pumphrey,Daniel Williams,Helen K. Tayton-Martin,Lilliam Ribeiro,Tom Holdich,Saul Yanovich,Nancy M. Hardy,Jean A. Yared,Naseem Kerr,Sunita Philip,Sandra Westphal,Don L. Siegel,Bruce L. Levine,Bent K. Jakobsen,Michael Kalos,Carl H. June +34 more
TL;DR: NY-ESO-1–LAGE-1 TCR–engineered T cells were safe, trafficked to marrow and showed extended persistence that correlated with clinical activity against antigen-positive myeloma, according to the expected mechanism of action of the transferred T cells.
Journal ArticleDOI
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
Li Tang,Yiran Zheng,Mariane B. Melo,Llian Mabardi,Ana P. Castano,Yu-Qing Xie,Na Li,Sagar B. Kudchodkar,Hing C. Wong,Emily K. Jeng,Marcela V. Maus,Darrell J. Irvine +11 more
TL;DR: In this article, protein nanogels (NGs) were used to carry an interleukin-15 super-agonist complex, which selectively released these cargos in response to T cell receptor activation.
Journal ArticleDOI
Adoptive cellular therapy: a race to the finish line.
TL;DR: Some of the challenges—such as regulatory, cost, and manufacturing—and opportunities, including personalized gene-modified T cells, that face the field of adoptive cellular therapy are discussed.
Journal ArticleDOI
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
TL;DR: Clinical results reflecting the investigational use of CD19-targeted CAR T-cell therapeutics in patients with B-cell hematologic malignancies are reviewed, in light of differences in CAR design and production, and the limitations inherent in comparing outcomes between studies are outlined.
Journal ArticleDOI
Advantages and applications of CAR-expressing natural killer cells.
Wolfgang Glienke,Ruth Esser,Christoph Priesner,Julia D. Suerth,Axel Schambach,Winfried S. Wels,Manuel Grez,Stephan Kloess,Lubomir Arseniev,Ulrike Koehl +9 more
TL;DR: This review summarizes the data on CAR expressing NK cells focusing on the possible advantage using these short-lived effector cells and discusses the necessity of suicide switches.
References
More filters
Journal ArticleDOI
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.
Jan-Inge Henter,AnnaCarin Horne,Maurizio Aricò,R. Maarten Egeler,Alexandra H. Filipovich,Shinsaku Imashuku,Stephan Ladisch,Kenneth L. McClain,David Webb,Jacek Winiarski,Gritta Janka +10 more
TL;DR: HLH‐2004 chemo‐immunotherapy includes etoposide, dexamethasone, cyclosporine A upfront and, in selected patients, intrathecal therapy with methotrexate and corticosteroids, and subsequent hematopoietic stem cell transplantation is recommended for patients with familial disease or molecular diagnosis, and patients with severe and persistent, or reactivated, disease.
Journal ArticleDOI
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
TL;DR: A low dose of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission.
Journal ArticleDOI
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A. Grupp,Michael Kalos,David M. Barrett,Richard Aplenc,David L. Porter,Susan R. Rheingold,David T. Teachey,Anne Chew,Bernd Hauck,J. Fraser Wright,Michael C. Milone,Bruce L. Levine,Carl H. June +12 more
TL;DR: The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL.
Journal ArticleDOI
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan,Mark E. Dudley,John R. Wunderlich,Michael S. Hughes,James Chih-Hsin Yang,Richard M. Sherry,Richard E. Royal,Suzanne L. Topalian,Udai S. Kammula,Nicholas P. Restifo,Zhili Zheng,Azam V. Nahvi,Christiaan R. de Vries,Linda Rogers-Freezer,Sharon Mavroukakis,Steven A. Rosenberg +15 more
TL;DR: The ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor is reported.
Journal ArticleDOI
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos,Bruce L. Levine,David L. Porter,Sharyn I. Katz,Stephan A. Grupp,Stephan A. Grupp,Adam Bagg,Carl H. June +7 more
TL;DR: It is reported that CAR T cells that target CD19 and contain a costimulatory domain from CD137 and the T cell receptor ζ chain have potent non–cross-resistant clinical activity after infusion in three of three patients treated with advanced chronic lymphocytic leukemia (CLL).
Related Papers (5)
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude,Noelle Frey,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Nancy Bunin,Anne Chew,Vanessa E. Gonzalez,Zhaohui Zheng,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Susan R. Rheingold,Angela Shen,David T. Teachey,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +18 more